👪

Inheritance

1

X-linked recessive HP:0001419

XDP is inherited in an X-linked manner. Affected individuals are almost exclusively male; female carriers are usually asymptomatic, although a small minority manifest dystonia, parkinsonism, or chorea.

X-linked recessive inheritance

Show evidence (2 references)

PMID:20301662 SUPPORT Human Clinical

"XDP is inherited in an X-linked manner."

GeneReviews states the X-linked inheritance pattern.

PMID:12928496 SUPPORT Human Clinical

"X-linked dystonia parkinsonism (XDP) is an X-linked recessive adult onset movement disorder characterized by both dystonia and parkinsonism."

Confirms X-linked recessive inheritance and the dystonia-parkinsonism phenotype.

◈

Mechanistic Hypotheses

2

G-quadruplex-mediated transcriptional interference at the XDP SVA

g4_transcriptional_interference EMERGING

The G-rich (CCCTCT)n hexameric repeat within the XDP SVA folds into stable G-quadruplex (G4) structures that interfere with TAF1 transcription. Pharmacologic stabilization of these G4s reduces TAF1 transcripts while destabilization (unfolding) increases TAF1 transcripts, implicating G4 formation as a major cause of aberrant TAF1 expression and a candidate therapeutic target.

Show evidence (2 references)

PMID:39287133 SUPPORT In Vitro

"Our data indicate that G4 formation in the XDP SVA is a major cause of aberrant TAF1 expression"

Establishes G-quadruplex formation in the XDP SVA as a major driver of aberrant TAF1 expression.

PMID:39287133 SUPPORT In Vitro

"stabilisation of the XDP SVA G4s reduces TAF1 transcripts downstream and around the SVA, and increases upstream transcripts, while destabilisation using the G4 unfolder PhpC increases TAF1 transcripts"

Demonstrates bidirectional pharmacologic modulation of TAF1 transcription by G4 ligands, supporting G4s as a causal and druggable mechanism.

ZNF91-dependent mini-heterochromatin constrains the XDP SVA

sva_epigenetic_repression EMERGING

An innate epigenetic defense system mediated by the KRAB zinc-finger protein ZNF91 deposits H3K9me3 and DNA methylation over SVA elements, forming mini-heterochromatin domains that attenuate the cis-regulatory impact of the XDP SVA. Loss of this local heterochromatin worsens the XDP molecular phenotype, increasing TAF1 intron retention and reducing TAF1 expression.

Show evidence (2 references)

PMID:38834915 SUPPORT In Vitro

"the KRAB zinc finger protein ZNF91 establishes H3K9me3 and DNA methylation over SVAs"

Identifies ZNF91-mediated heterochromatin as the epigenetic control system over SVA elements.

PMID:38834915 SUPPORT In Vitro

"removal of local heterochromatin severely aggravates the XDP molecular phenotype, resulting in increased TAF1 intron retention and reduced expression"

Shows that loss of SVA heterochromatin worsens TAF1 intron retention and reduces expression, linking epigenetic repression to the XDP molecular phenotype.

⚙

Pathophysiology

3

SVA retrotransposon insertion in TAF1

A disease-specific SINE-VNTR-Alu (SVA) retrotransposon is inserted in an intron of TAF1 (intron 32). The element includes a polymorphic (CCCTCT)n hexanucleotide repeat whose length is inversely correlated with age at disease onset. This is the founding genetic lesion of XDP.

TAF1 hgnc:11535

Downstream

TAF1 transcriptional dysregulation The intronic SVA alters TAF1 splicing and reduces full-length TAF1 transcript levels in neurons.

Show evidence (2 references)

PMID:29474918 SUPPORT Human Clinical

"We integrated multiple genome and transcriptome assembly technologies to narrow the causal mutation to the TAF1 locus, which included a SINE-VNTR-Alu (SVA) retrotransposition into intron 32 of the gene."

Localizes the causal SVA insertion to intron 32 of TAF1.

PMID:17273961 SUPPORT Human Clinical

"We found a disease-specific SVA (short interspersed nuclear element, variable number of tandem repeats, and Alu composite) retrotransposon insertion in an intron of the TATA-binding protein-associated factor 1 gene (TAF1)"

Original identification of the disease-specific SVA insertion in TAF1.

TAF1 transcriptional dysregulation

The SVA reduces neuron-specific expression of the canonical full-length cTAF1 transcript and induces aberrant transcription, alternative splicing, and intron retention in proximity to the SVA. TAF1 encodes the largest subunit of the general transcription factor TFIID, so reduced TAF1 impairs RNA polymerase II transcription. CRISPR/Cas9 excision of the SVA rescues the XDP-specific transcriptional signature and normalizes TAF1 expression.

regulation of RNA polymerase II transcription GO:0006357 ↓ DECREASED aberrant mRNA splicing and intron retention GO:0000398 ⚠ ABNORMAL

Downstream

Striatal medium spiny neuron degeneration Neuron-specific TAF1 transcriptional dysregulation drives progressive loss of striatal (neostriatal) neurons.

Show evidence (5 references)

PMID:29474918 SUPPORT In Vitro

"Transcriptome analyses identified decreased expression of the canonical cTAF1 transcript among XDP probands, and de novo assembly across multiple pluripotent stem-cell-derived neuronal lineages discovered aberrant TAF1 transcription that involved alternative splicing and intron retention (IR) in..."

Demonstrates decreased canonical TAF1 transcript and SVA-associated aberrant splicing and intron retention.

PMID:29474918 SUPPORT In Vitro

"CRISPR/Cas9 excision of the SVA rescued this XDP-specific transcriptional signature and normalized TAF1 expression in probands."

Establishes the SVA as causal for the transcriptional defect via rescue on excision.

PMID:17273961 SUPPORT Human Clinical

"significantly decreased expression levels of TAF1 and the dopamine receptor D2 gene (DRD2) in the caudate nucleus"

Shows reduced TAF1 (and DRD2) expression in patient caudate.

+ 2 more references

Striatal medium spiny neuron degeneration

The major neuropathology of XDP is progressive neuronal loss in the neostriatum (caudate nucleus and putamen), the site enriched for GABAergic medium spiny neurons. Post-mortem studies show a marked loss of striatal neuropeptide Y-positive neurons and nerve fibres in the caudate and putamen, implicating loss of striatal neuronal populations in the progressive degeneration. Striatal neurodegeneration is thought to produce the dystonia and parkinsonism of XDP.

striatal medium spiny neuron CL:1001474 ↓ DECREASED

striatal neuron apoptotic process GO:0051402 ↑ INCREASED

neostriatum (caudate nucleus and putamen) UBERON:0005383

Show evidence (4 references)

PMID:28672841 SUPPORT Human Clinical

"The major neuropathology of XDP is progressive neuronal loss in the neostriatum (i.e., the caudate nucleus and putamen)."

Documents progressive neostriatal neuronal loss as the major neuropathology.

PMID:23599389 SUPPORT Human Clinical

"In patients with X-linked dystonia-parkinsonism, we found a significant decrease in the number of neuropeptide Y-positive cells accompanied by a marked loss of their nerve fibres in the caudate nucleus and putamen."

Post-mortem evidence of striatal neuronal loss (neuropeptide Y neurons) in caudate and putamen.

PMID:23599389 PARTIAL Human Clinical

"suggesting its possible implication in the mechanism by which a progressive loss of striatal neurons occurs in X-linked dystonia-parkinsonism"

Connects striatal neuropeptide Y system defects to the progressive loss of striatal neurons.

+ 1 more reference

⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.

●

Phenotypes

12

Digestive 1

Dysphagia Dysphagia HP:0002015

Show evidence (1 reference)

PMID:20301662 SUPPORT Human Clinical

"Botulinum toxin injections improve focal dystonia but may worsen swallowing in individuals with preexisting dysphagia."

GeneReviews documents dysphagia as a clinically relevant feature in XDP.

Head and Neck 1

Hyposmia Hyposmia HP:0004409

Show evidence (1 reference)

PMID:20301662 SUPPORT Human Clinical

"Olfactory testing indicates olfactory dysfunction early in the disease and may be used to support the diagnosis when molecular genetic testing is not available."

GeneReviews documents early olfactory dysfunction in XDP.

Musculoskeletal 1

Rigidity Rigidity HP:0002063

Show evidence (1 reference)

PMID:20301662 SUPPORT Human Clinical

"Features of parkinsonism include resting tremor, bradykinesia, rigidity, postural instability, and severe shuffling gait."

GeneReviews lists rigidity among XDP parkinsonian features.

Nervous System 6

Dystonia Dystonia HP:0001332

Course: PROGRESSIVE

Show evidence (1 reference)

PMID:20301662 SUPPORT Human Clinical

"The dystonia develops focally, most commonly in the jaw, neck, trunk, and eyes, and less commonly in the limbs, tongue, pharynx, and larynx, the most characteristic being jaw dystonia often progressing to neck dystonia."

GeneReviews describes the focal-to-generalized dystonia distribution.

Parkinsonism Parkinsonism HP:0001300

Show evidence (1 reference)

PMID:20301662 SUPPORT Human Clinical

"Features of parkinsonism include resting tremor, bradykinesia, rigidity, postural instability, and severe shuffling gait."

GeneReviews enumerates the parkinsonian features of XDP.

Resting tremor Resting tremor HP:0002322

Show evidence (1 reference)

PMID:20301662 SUPPORT Human Clinical

"Features of parkinsonism include resting tremor, bradykinesia, rigidity, postural instability, and severe shuffling gait."

GeneReviews lists resting tremor among XDP parkinsonian features.

Bradykinesia Bradykinesia HP:0002067

Show evidence (1 reference)

PMID:20301662 SUPPORT Human Clinical

"Features of parkinsonism include resting tremor, bradykinesia, rigidity, postural instability, and severe shuffling gait."

GeneReviews lists bradykinesia among XDP parkinsonian features.

Postural instability Postural instability HP:0002172

Show evidence (1 reference)

PMID:20301662 SUPPORT Human Clinical

"Features of parkinsonism include resting tremor, bradykinesia, rigidity, postural instability, and severe shuffling gait."

GeneReviews lists postural instability among XDP parkinsonian features.

Chorea Chorea HP:0002072

Show evidence (1 reference)

PMID:20301662 SUPPORT Human Clinical

"Female carriers are mostly asymptomatic, though a small minority may manifest dystonia, parkinsonism, or chorea."

GeneReviews documents chorea as part of the XDP phenotypic spectrum.

Other 3

Oromandibular (jaw) dystonia Oromandibular dystonia HP:0012048

Show evidence (1 reference)

PMID:20301662 SUPPORT Human Clinical

"the most characteristic being jaw dystonia often progressing to neck dystonia"

GeneReviews identifies jaw (oromandibular) dystonia as the most characteristic focal site.

Generalized dystonia Generalized dystonia HP:0007325

Show evidence (1 reference)

PMID:20301662 SUPPORT Human Clinical

"those who develop a combination of parkinsonism and dystonia can develop multifocal or generalized symptoms within a few years"

GeneReviews documents progression to generalized dystonia.

Shuffling gait Shuffling gait HP:0002362

Show evidence (1 reference)

PMID:20301662 SUPPORT Human Clinical

"Features of parkinsonism include resting tremor, bradykinesia, rigidity, postural instability, and severe shuffling gait."

GeneReviews lists severe shuffling gait among XDP parkinsonian features.

🧬

Genetic Associations

1

TAF1

Gene: TAF1 hgnc:11535

X-linked recessive

Show evidence (4 references)

PMID:29229810 SUPPORT Human Clinical

"X-linked dystonia-parkinsonism (XDP) is a neurodegenerative disease associated with an antisense insertion of a SINE-VNTR-Alu (SVA)-type retrotransposon within an intron of TAF1"

Describes the antisense SVA retrotransposon insertion in TAF1.

PMID:29229810 SUPPORT Human Clinical

"we examined the sequence of this SVA in XDP patients (n = 140) and detected polymorphic variation in the length of a hexanucleotide repeat domain, (CCCTCT)n The number of repeats in these cases ranged from 35 to 52 and showed a highly significant inverse correlation with age at disease onset."

Establishes the (CCCTCT)n hexanucleotide repeat and its inverse correlation with age at onset.

PMID:30973967 SUPPORT Human Clinical

"RN showed significant inverse correlations with AAO and with TAF1 expression and a positive correlation with disease severity and cognitive dysfunction."

Confirms the hexanucleotide repeat as a modifier of onset, TAF1 expression, and severity.

+ 1 more reference

💊

Medical Actions

5

Anticholinergic therapy

Action: pharmacotherapy MAXO:0000058

Agent: trihexyphenidyl CHEBI:9720

Anticholinergic agents (e.g., trihexyphenidyl) are used in the early stages of dystonia in XDP.

Target Phenotypes: Dystonia HP:0001332

Show evidence (1 reference)

PMID:20301662 SUPPORT Human Clinical

"Anticholinergic agents, benzodiazepines, and sometimes neuroleptics are used in the early stages of dystonia"

GeneReviews recommends anticholinergic agents for early-stage dystonia.

Tetrabenazine and zolpidem

Action: pharmacotherapy MAXO:0000058

Agent: tetrabenazine CHEBI:9467 zolpidem CHEBI:10125

Zolpidem and tetrabenazine are used after dystonia becomes multifocal or generalized.

Target Phenotypes: Generalized dystonia HP:0007325

Show evidence (1 reference)

PMID:20301662 SUPPORT Human Clinical

"zolpidem and tetrabenazine are used after dystonia becomes multifocal or generalized"

GeneReviews recommends zolpidem and tetrabenazine for multifocal/generalized dystonia.

Botulinum toxin injection

Action: botulinum toxin type A therapy MAXO:0009016

Botulinum toxin injections improve focal dystonia but may worsen swallowing in individuals with preexisting dysphagia.

Target Phenotypes: Oromandibular dystonia HP:0012048

Show evidence (1 reference)

PMID:20301662 SUPPORT Human Clinical

"Botulinum toxin injections improve focal dystonia but may worsen swallowing in individuals with preexisting dysphagia."

GeneReviews documents botulinum toxin for focal dystonia and its dysphagia caution.

Levodopa and dopamine agonists

Action: pharmacotherapy MAXO:0000058

Agent: levodopa CHEBI:15765

Parkinsonism in XDP is treated with levodopa and dopamine agonists to control tremor.

Target Phenotypes: Parkinsonism HP:0001300

Show evidence (1 reference)

PMID:20301662 SUPPORT Human Clinical

"Parkinsonism is treated with levodopa and dopamine agonists to control tremor."

GeneReviews recommends levodopa and dopamine agonists for XDP parkinsonism.

Bilateral pallidal deep brain stimulation

Action: deep brain stimulation MAXO:0000943

Bilateral pallidal deep brain stimulation may be used to treat advanced disease and medically refractory dystonia, although it may have less effect on parkinsonism. In patients with combined dystonia and parkinsonism, pallidal DBS has produced rapid improvement of hyperkinetic movements, but effects on hypokinetic features have been inconsistent.

Target Phenotypes: Generalized dystonia HP:0007325

Show evidence (2 references)

PMID:20301662 SUPPORT Human Clinical

"Bilateral pallidal deep brain stimulation may be used to treat advanced disease and medically refractory dystonia, although it may have less effect on parkinsonism."

GeneReviews documents pallidal DBS for advanced/refractory dystonia.

PMID:31116117 SUPPORT Human Clinical

"In patients exhibiting features of both dystonia and parkinsonism, pallidal DBS has resulted in rapid improvement of hyperkinetic movements, but effects on hypokinetic features have been inconsistent."

Confirms DBS benefit for hyperkinetic (dystonic) features with inconsistent effect on parkinsonism.

🔬

Clinical Trials

1

NCT05592028

Bilateral transcranial magnetic resonance-guided focused ultrasound (MRgFUS) pallidothalamic tractotomy for patients with genetically confirmed X-linked dystonia-parkinsonism, conducted at the Philippine General Hospital. The primary outcome is change in the XDP-Movement Disorder Society of the Philippines Scale; secondary measures include the Burke-Fahn-Marsden Dystonia Rating Scale and MDS-UPDRS Part III.

Target Phenotypes: Dystonia HP:0001332 Parkinsonism HP:0001300

Show evidence (1 reference)

PMID:37596524 SUPPORT Human Clinical

"This study aims to determine the improvement in dystonia and parkinsonism in patients with XDP after MRgFUS pallidothalamic tractotomy."

The registered protocol (NCT05592028) evaluates MRgFUS pallidothalamic tractotomy for dystonia and parkinsonism in XDP.

{ }

Source YAML

click to show

name: X-linked Dystonia-Parkinsonism
creation_date: "2026-06-03T00:00:00Z"
category: Mendelian
disease_term:
  preferred_term: X-linked dystonia-parkinsonism
  term:
    id: MONDO:0010747
    label: X-linked dystonia-parkinsonism
parents:
  - focal dystonia
  - combined dystonia
  - parkinsonian disorder
synonyms:
  - XDP
  - DYT3
  - Lubag
  - DYT-TAF1
  - X-linked torsion dystonia-parkinsonism
description: >
  X-linked dystonia-parkinsonism (XDP; DYT3; "Lubag") is an X-linked recessive,
  adult-onset neurodegenerative movement disorder endemic to the island of
  Panay, Philippines. It is caused by a disease-specific SINE-VNTR-Alu (SVA)
  retrotransposon insertion in intron 32 of the TAF1 gene, which encodes the
  largest subunit of the general transcription factor TFIID. The insertion
  carries a polymorphic (CCCTCT)n hexanucleotide repeat whose length inversely
  correlates with age at onset. The SVA reduces expression of the canonical
  full-length TAF1 transcript and induces aberrant splicing and intron
  retention, producing a neuron-specific transcriptional dysregulation that
  drives progressive degeneration of the neostriatum (caudate nucleus and
  putamen). Affected men typically present in mid-adulthood with focal dystonia
  that generalizes over years, later accompanied or replaced by parkinsonism;
  female carriers are mostly asymptomatic.

references:
  - reference: PMID:20301662
    title: "X-Linked Dystonia-Parkinsonism."
    tags:
      - GeneReviews

inheritance:
  - name: X-linked recessive
    inheritance_term:
      preferred_term: X-linked recessive inheritance
      term:
        id: HP:0001419
        label: X-linked recessive inheritance
    description: >
      XDP is inherited in an X-linked manner. Affected individuals are almost
      exclusively male; female carriers are usually asymptomatic, although a
      small minority manifest dystonia, parkinsonism, or chorea.
    evidence:
      - reference: PMID:20301662
        reference_title: "X-Linked Dystonia-Parkinsonism."
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: "XDP is inherited in an X-linked manner."
        explanation: GeneReviews states the X-linked inheritance pattern.
      - reference: PMID:12928496
        reference_title: "Specific sequence changes in multiple transcript system DYT3 are associated with X-linked dystonia parkinsonism."
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: "X-linked dystonia parkinsonism (XDP) is an X-linked recessive adult onset movement disorder characterized by both dystonia and parkinsonism."
        explanation: Confirms X-linked recessive inheritance and the dystonia-parkinsonism phenotype.

epidemiology:
  - name: Endemic to Panay, Philippines
    description: >
      XDP is endemic to the island of Panay in the Philippines and affects men
      whose maternal ancestry traces to Panay; the disorder is associated with a
      single shared founder haplotype.
    evidence:
      - reference: PMID:37265597
        reference_title: "Establishing a natural history of X-linked dystonia parkinsonism."
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: "X-linked dystonia parkinsonism is a neurodegenerative movement disorder that affects men whose mothers originate from the island of Panay, Philippines."
        explanation: Establishes the endemic geographic and maternal-ancestry distribution.
      - reference: PMID:29474918
        reference_title: "Dissecting the Causal Mechanism of X-Linked Dystonia-Parkinsonism by Integrating Genome and Transcriptome Assembly."
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: "X-linked Dystonia-Parkinsonism (XDP) is a Mendelian neurodegenerative disease that is endemic to the Philippines and is associated with a founder haplotype."
        explanation: Confirms endemicity to the Philippines and the founder haplotype.

prevalence:
  - population: Panay, Philippines (males)
    notes: >
      XDP is a rare disorder primarily affecting Filipino men with maternal
      ancestry from Panay; reported prevalence is highest in this endemic
      population and rare elsewhere.
    evidence:
      - reference: PMID:20301662
        reference_title: "X-Linked Dystonia-Parkinsonism."
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: "XDP afflicts primarily Filipino men and, rarely, women."
        explanation: GeneReviews notes the disorder primarily affects Filipino men and rarely women.

progression:
  - phase: Onset and course
    notes: >
      Mean age of onset in men is 39 years. The clinical course is highly
      variable: parkinsonism may be the initial presenting sign and is later
      overshadowed by dystonia as the disease progresses. Individuals who
      develop combined parkinsonism and dystonia can progress to multifocal or
      generalized symptoms within a few years and die prematurely from pneumonia
      or intercurrent infections.
    evidence:
      - reference: PMID:20301662
        reference_title: "X-Linked Dystonia-Parkinsonism."
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: "The mean age of onset in men is 39 years; the clinical course is highly variable with parkinsonism as the initial presenting sign, overshadowed by dystonia as the disease progresses."
        explanation: GeneReviews describes the age of onset and progressive course.
      - reference: PMID:20301662
        reference_title: "X-Linked Dystonia-Parkinsonism."
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: "those who develop a combination of parkinsonism and dystonia can develop multifocal or generalized symptoms within a few years and die prematurely from pneumonia or intercurrent infections"
        explanation: Documents progression to generalized disease and premature death from infection.

phenotypes:
  - name: Dystonia
    description: >
      Dystonia develops focally, most commonly in the jaw, neck, trunk, and
      eyes, and generalizes over time. Jaw dystonia often progressing to neck
      dystonia is the most characteristic feature.
    phenotype_term:
      preferred_term: Dystonia
      term:
        id: HP:0001332
        label: Dystonia
      clinical_course: PROGRESSIVE
    evidence:
      - reference: PMID:20301662
        reference_title: "X-Linked Dystonia-Parkinsonism."
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: "The dystonia develops focally, most commonly in the jaw, neck, trunk, and eyes, and less commonly in the limbs, tongue, pharynx, and larynx, the most characteristic being jaw dystonia often progressing to neck dystonia."
        explanation: GeneReviews describes the focal-to-generalized dystonia distribution.
  - name: Oromandibular (jaw) dystonia
    description: >
      Jaw dystonia is among the most characteristic focal presentations and
      often progresses to neck dystonia.
    phenotype_term:
      preferred_term: Oromandibular dystonia
      term:
        id: HP:0012048
        label: Oromandibular dystonia
    evidence:
      - reference: PMID:20301662
        reference_title: "X-Linked Dystonia-Parkinsonism."
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: "the most characteristic being jaw dystonia often progressing to neck dystonia"
        explanation: GeneReviews identifies jaw (oromandibular) dystonia as the most characteristic focal site.
  - name: Generalized dystonia
    description: >
      Focal dystonia becomes multifocal or generalized over time, particularly
      in individuals who develop combined dystonia and parkinsonism.
    phenotype_term:
      preferred_term: Generalized dystonia
      term:
        id: HP:0007325
        label: Generalized dystonia
    evidence:
      - reference: PMID:20301662
        reference_title: "X-Linked Dystonia-Parkinsonism."
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: "those who develop a combination of parkinsonism and dystonia can develop multifocal or generalized symptoms within a few years"
        explanation: GeneReviews documents progression to generalized dystonia.
  - name: Parkinsonism
    description: >
      Adult-onset parkinsonism that may be the initial presenting sign and
      includes resting tremor, bradykinesia, rigidity, and postural instability.
    phenotype_term:
      preferred_term: Parkinsonism
      term:
        id: HP:0001300
        label: Parkinsonism
    evidence:
      - reference: PMID:20301662
        reference_title: "X-Linked Dystonia-Parkinsonism."
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: "Features of parkinsonism include resting tremor, bradykinesia, rigidity, postural instability, and severe shuffling gait."
        explanation: GeneReviews enumerates the parkinsonian features of XDP.
  - name: Resting tremor
    description: Resting tremor as a feature of XDP parkinsonism.
    phenotype_term:
      preferred_term: Resting tremor
      term:
        id: HP:0002322
        label: Resting tremor
    evidence:
      - reference: PMID:20301662
        reference_title: "X-Linked Dystonia-Parkinsonism."
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: "Features of parkinsonism include resting tremor, bradykinesia, rigidity, postural instability, and severe shuffling gait."
        explanation: GeneReviews lists resting tremor among XDP parkinsonian features.
  - name: Bradykinesia
    description: Bradykinesia as a feature of XDP parkinsonism.
    phenotype_term:
      preferred_term: Bradykinesia
      term:
        id: HP:0002067
        label: Bradykinesia
    evidence:
      - reference: PMID:20301662
        reference_title: "X-Linked Dystonia-Parkinsonism."
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: "Features of parkinsonism include resting tremor, bradykinesia, rigidity, postural instability, and severe shuffling gait."
        explanation: GeneReviews lists bradykinesia among XDP parkinsonian features.
  - name: Rigidity
    description: Rigidity as a feature of XDP parkinsonism.
    phenotype_term:
      preferred_term: Rigidity
      term:
        id: HP:0002063
        label: Rigidity
    evidence:
      - reference: PMID:20301662
        reference_title: "X-Linked Dystonia-Parkinsonism."
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: "Features of parkinsonism include resting tremor, bradykinesia, rigidity, postural instability, and severe shuffling gait."
        explanation: GeneReviews lists rigidity among XDP parkinsonian features.
  - name: Postural instability
    description: Postural instability as a feature of XDP parkinsonism.
    phenotype_term:
      preferred_term: Postural instability
      term:
        id: HP:0002172
        label: Postural instability
    evidence:
      - reference: PMID:20301662
        reference_title: "X-Linked Dystonia-Parkinsonism."
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: "Features of parkinsonism include resting tremor, bradykinesia, rigidity, postural instability, and severe shuffling gait."
        explanation: GeneReviews lists postural instability among XDP parkinsonian features.
  - name: Shuffling gait
    description: Severe shuffling gait as a feature of XDP parkinsonism.
    phenotype_term:
      preferred_term: Shuffling gait
      term:
        id: HP:0002362
        label: Shuffling gait
    evidence:
      - reference: PMID:20301662
        reference_title: "X-Linked Dystonia-Parkinsonism."
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: "Features of parkinsonism include resting tremor, bradykinesia, rigidity, postural instability, and severe shuffling gait."
        explanation: GeneReviews lists severe shuffling gait among XDP parkinsonian features.
  - name: Hyposmia
    description: >
      Olfactory dysfunction occurs early in the disease and may be used to
      support the diagnosis when molecular genetic testing is unavailable.
    phenotype_term:
      preferred_term: Hyposmia
      term:
        id: HP:0004409
        label: Hyposmia
    evidence:
      - reference: PMID:20301662
        reference_title: "X-Linked Dystonia-Parkinsonism."
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: "Olfactory testing indicates olfactory dysfunction early in the disease and may be used to support the diagnosis when molecular genetic testing is not available."
        explanation: GeneReviews documents early olfactory dysfunction in XDP.
  - name: Dysphagia
    description: >
      Swallowing impairment is a complication of XDP; botulinum toxin may worsen
      swallowing in individuals with preexisting dysphagia, and swallowing
      evaluations are recommended to minimize aspiration risk.
    phenotype_term:
      preferred_term: Dysphagia
      term:
        id: HP:0002015
        label: Dysphagia
    evidence:
      - reference: PMID:20301662
        reference_title: "X-Linked Dystonia-Parkinsonism."
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: "Botulinum toxin injections improve focal dystonia but may worsen swallowing in individuals with preexisting dysphagia."
        explanation: GeneReviews documents dysphagia as a clinically relevant feature in XDP.
  - name: Chorea
    description: >
      A small minority of female carriers may manifest chorea, and chorea may
      occur in the phenotypic spectrum of XDP without dystonia.
    phenotype_term:
      preferred_term: Chorea
      term:
        id: HP:0002072
        label: Chorea
    evidence:
      - reference: PMID:20301662
        reference_title: "X-Linked Dystonia-Parkinsonism."
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: "Female carriers are mostly asymptomatic, though a small minority may manifest dystonia, parkinsonism, or chorea."
        explanation: GeneReviews documents chorea as part of the XDP phenotypic spectrum.

pathophysiology:
  - name: SVA retrotransposon insertion in TAF1
    description: >
      A disease-specific SINE-VNTR-Alu (SVA) retrotransposon is inserted in an
      intron of TAF1 (intron 32). The element includes a polymorphic (CCCTCT)n
      hexanucleotide repeat whose length is inversely correlated with age at
      disease onset. This is the founding genetic lesion of XDP.
    genes:
      - preferred_term: TAF1
        term:
          id: hgnc:11535
          label: TAF1
    evidence:
      - reference: PMID:29474918
        reference_title: "Dissecting the Causal Mechanism of X-Linked Dystonia-Parkinsonism by Integrating Genome and Transcriptome Assembly."
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: "We integrated multiple genome and transcriptome assembly technologies to narrow the causal mutation to the TAF1 locus, which included a SINE-VNTR-Alu (SVA) retrotransposition into intron 32 of the gene."
        explanation: Localizes the causal SVA insertion to intron 32 of TAF1.
      - reference: PMID:17273961
        reference_title: "Reduced neuron-specific expression of the TAF1 gene is associated with X-linked dystonia-parkinsonism."
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: "We found a disease-specific SVA (short interspersed nuclear element, variable number of tandem repeats, and Alu composite) retrotransposon insertion in an intron of the TATA-binding protein-associated factor 1 gene (TAF1)"
        explanation: Original identification of the disease-specific SVA insertion in TAF1.
    downstream:
      - target: TAF1 transcriptional dysregulation
        description: >
          The intronic SVA alters TAF1 splicing and reduces full-length TAF1
          transcript levels in neurons.
        evidence:
          - reference: PMID:31116117
            reference_title: "X-Linked Dystonia-Parkinsonism: recent advances."
            supports: SUPPORT
            evidence_source: IN_VITRO
            snippet: "In cell models, the SVA alters TAF1 splicing and reduces levels of full-length transcript."
            explanation: Links the SVA insertion to altered splicing and reduced TAF1 transcript.
  - name: TAF1 transcriptional dysregulation
    description: >
      The SVA reduces neuron-specific expression of the canonical full-length
      cTAF1 transcript and induces aberrant transcription, alternative splicing,
      and intron retention in proximity to the SVA. TAF1 encodes the largest
      subunit of the general transcription factor TFIID, so reduced TAF1 impairs
      RNA polymerase II transcription. CRISPR/Cas9 excision of the SVA rescues
      the XDP-specific transcriptional signature and normalizes TAF1 expression.
    biological_processes:
      - preferred_term: regulation of RNA polymerase II transcription
        term:
          id: GO:0006357
          label: regulation of transcription by RNA polymerase II
        modifier: DECREASED
      - preferred_term: aberrant mRNA splicing and intron retention
        term:
          id: GO:0000398
          label: mRNA splicing, via spliceosome
        modifier: ABNORMAL
    evidence:
      - reference: PMID:29474918
        reference_title: "Dissecting the Causal Mechanism of X-Linked Dystonia-Parkinsonism by Integrating Genome and Transcriptome Assembly."
        supports: SUPPORT
        evidence_source: IN_VITRO
        snippet: "Transcriptome analyses identified decreased expression of the canonical cTAF1 transcript among XDP probands, and de novo assembly across multiple pluripotent stem-cell-derived neuronal lineages discovered aberrant TAF1 transcription that involved alternative splicing and intron retention (IR) in proximity to the SVA that was anti-correlated with overall TAF1 expression."
        explanation: Demonstrates decreased canonical TAF1 transcript and SVA-associated aberrant splicing and intron retention.
      - reference: PMID:29474918
        reference_title: "Dissecting the Causal Mechanism of X-Linked Dystonia-Parkinsonism by Integrating Genome and Transcriptome Assembly."
        supports: SUPPORT
        evidence_source: IN_VITRO
        snippet: "CRISPR/Cas9 excision of the SVA rescued this XDP-specific transcriptional signature and normalized TAF1 expression in probands."
        explanation: Establishes the SVA as causal for the transcriptional defect via rescue on excision.
      - reference: PMID:17273961
        reference_title: "Reduced neuron-specific expression of the TAF1 gene is associated with X-linked dystonia-parkinsonism."
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: "significantly decreased expression levels of TAF1 and the dopamine receptor D2 gene (DRD2) in the caudate nucleus"
        explanation: Shows reduced TAF1 (and DRD2) expression in patient caudate.
      - reference: PMID:28672841
        reference_title: "Clinicopathological Phenotype and Genetics of X-Linked Dystonia-Parkinsonism (XDP; DYT3; Lubag)."
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: "XDP has been identified as a transcriptional dysregulation syndrome with impaired expression of the TAF1 (TATA box-binding protein associated factor 1) gene, which is a critical component of the cellular transcription machinery."
        explanation: Frames XDP as a transcriptional dysregulation syndrome driven by impaired TAF1.
      - reference: PMID:38042508
        reference_title: "Proteomic analysis of X-linked dystonia parkinsonism disease striatal neurons reveals altered RNA metabolism and splicing."
        supports: SUPPORT
        evidence_source: IN_VITRO
        snippet: "The genetic cause for XDP is an insertion of a SINE-VNTR-Alu (SVA)-type retrotransposon within intron 32 of TATA-binding protein associated factor 1 (TAF1) that causes an alteration of TAF1 splicing, partial intron retention, and decreased transcription."
        explanation: Independent confirmation that the SVA causes altered TAF1 splicing, partial intron retention, and decreased transcription.
    downstream:
      - target: Striatal medium spiny neuron degeneration
        description: >
          Neuron-specific TAF1 transcriptional dysregulation drives progressive
          loss of striatal (neostriatal) neurons.
        evidence:
          - reference: PMID:28672841
            reference_title: "Clinicopathological Phenotype and Genetics of X-Linked Dystonia-Parkinsonism (XDP; DYT3; Lubag)."
            supports: SUPPORT
            evidence_source: HUMAN_CLINICAL
            snippet: "The major neuropathology of XDP is progressive neuronal loss in the neostriatum (i.e., the caudate nucleus and putamen)."
            explanation: Links the molecular defect to neostriatal neurodegeneration.
  - name: Striatal medium spiny neuron degeneration
    description: >
      The major neuropathology of XDP is progressive neuronal loss in the
      neostriatum (caudate nucleus and putamen), the site enriched for GABAergic
      medium spiny neurons. Post-mortem studies show a marked loss of striatal
      neuropeptide Y-positive neurons and nerve fibres in the caudate and
      putamen, implicating loss of striatal neuronal populations in the
      progressive degeneration. Striatal neurodegeneration is thought to produce
      the dystonia and parkinsonism of XDP.
    cell_types:
      - preferred_term: striatal medium spiny neuron
        term:
          id: CL:1001474
          label: medium spiny neuron
        modifier: DECREASED
    locations:
      - preferred_term: neostriatum (caudate nucleus and putamen)
        term:
          id: UBERON:0005383
          label: caudate-putamen
    biological_processes:
      - preferred_term: striatal neuron apoptotic process
        term:
          id: GO:0051402
          label: neuron apoptotic process
        modifier: INCREASED
    evidence:
      - reference: PMID:28672841
        reference_title: "Clinicopathological Phenotype and Genetics of X-Linked Dystonia-Parkinsonism (XDP; DYT3; Lubag)."
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: "The major neuropathology of XDP is progressive neuronal loss in the neostriatum (i.e., the caudate nucleus and putamen)."
        explanation: Documents progressive neostriatal neuronal loss as the major neuropathology.
      - reference: PMID:23599389
        reference_title: "Defects in the striatal neuropeptide Y system in X-linked dystonia-parkinsonism."
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: "In patients with X-linked dystonia-parkinsonism, we found a significant decrease in the number of neuropeptide Y-positive cells accompanied by a marked loss of their nerve fibres in the caudate nucleus and putamen."
        explanation: Post-mortem evidence of striatal neuronal loss (neuropeptide Y neurons) in caudate and putamen.
      - reference: PMID:23599389
        reference_title: "Defects in the striatal neuropeptide Y system in X-linked dystonia-parkinsonism."
        supports: PARTIAL
        evidence_source: HUMAN_CLINICAL
        snippet: "suggesting its possible implication in the mechanism by which a progressive loss of striatal neurons occurs in X-linked dystonia-parkinsonism"
        explanation: Connects striatal neuropeptide Y system defects to the progressive loss of striatal neurons.
      - reference: PMID:38042508
        reference_title: "Proteomic analysis of X-linked dystonia parkinsonism disease striatal neurons reveals altered RNA metabolism and splicing."
        supports: SUPPORT
        evidence_source: IN_VITRO
        snippet: "Although TAF1 is expressed in all organs, medium spiny neurons (MSNs) within the striatum are one of the cell types most affected in XDP."
        explanation: Identifies striatal medium spiny neurons as the most affected cell type, consistent with selective MSN vulnerability.

genetic:
  - name: TAF1
    gene_term:
      preferred_term: TAF1
      term:
        id: hgnc:11535
        label: TAF1
    inheritance:
      - name: X-linked recessive
        inheritance_term:
          preferred_term: X-linked recessive inheritance
          term:
            id: HP:0001419
            label: X-linked recessive inheritance
        evidence:
          - reference: PMID:12928496
            reference_title: "Specific sequence changes in multiple transcript system DYT3 are associated with X-linked dystonia parkinsonism."
            supports: SUPPORT
            evidence_source: HUMAN_CLINICAL
            snippet: "X-linked dystonia parkinsonism (XDP) is an X-linked recessive adult onset movement disorder characterized by both dystonia and parkinsonism."
            explanation: Confirms the X-linked recessive inheritance pattern of the TAF1-associated disorder.
    notes: >
      XDP is caused by an antisense SINE-VNTR-Alu (SVA) retrotransposon insertion
      within an intron of TAF1, inherited together with additional noncoding
      sequence changes as a single shared founder haplotype in all reported
      cases. A polymorphic (CCCTCT)n hexanucleotide repeat within the SVA is an
      age-at-onset and expressivity modifier: repeat length is inversely
      correlated with age at onset and positively correlated with disease
      severity and TAF1 repression.
    evidence:
      - reference: PMID:29229810
        reference_title: "Disease onset in X-linked dystonia-parkinsonism correlates with expansion of a hexameric repeat within an SVA retrotransposon in TAF1."
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: "X-linked dystonia-parkinsonism (XDP) is a neurodegenerative disease associated with an antisense insertion of a SINE-VNTR-Alu (SVA)-type retrotransposon within an intron of TAF1"
        explanation: Describes the antisense SVA retrotransposon insertion in TAF1.
      - reference: PMID:29229810
        reference_title: "Disease onset in X-linked dystonia-parkinsonism correlates with expansion of a hexameric repeat within an SVA retrotransposon in TAF1."
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: "we examined the sequence of this SVA in XDP patients (n = 140) and detected polymorphic variation in the length of a hexanucleotide repeat domain, (CCCTCT)n The number of repeats in these cases ranged from 35 to 52 and showed a highly significant inverse correlation with age at disease onset."
        explanation: Establishes the (CCCTCT)n hexanucleotide repeat and its inverse correlation with age at onset.
      - reference: PMID:30973967
        reference_title: "A hexanucleotide repeat modifies expressivity of X-linked dystonia parkinsonism."
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: "RN showed significant inverse correlations with AAO and with TAF1 expression and a positive correlation with disease severity and cognitive dysfunction."
        explanation: Confirms the hexanucleotide repeat as a modifier of onset, TAF1 expression, and severity.
      - reference: PMID:12928496
        reference_title: "Specific sequence changes in multiple transcript system DYT3 are associated with X-linked dystonia parkinsonism."
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: "Two of these transcripts include distal portions of the TAF1 gene (TATA-box binding protein-associated factor 1) and are alternatively spliced."
        explanation: Early mapping of the DYT3 locus to the TAF1 multiple transcript system.

treatments:
  - name: Anticholinergic therapy
    description: >
      Anticholinergic agents (e.g., trihexyphenidyl) are used in the early
      stages of dystonia in XDP.
    therapeutic_modality: SMALL_MOLECULE
    treatment_term:
      preferred_term: pharmacotherapy
      term:
        id: MAXO:0000058
        label: pharmacotherapy
      therapeutic_agent:
        - preferred_term: trihexyphenidyl
          term:
            id: CHEBI:9720
            label: Trihexyphenidyl
    target_phenotypes:
      - preferred_term: Dystonia
        term:
          id: HP:0001332
          label: Dystonia
    evidence:
      - reference: PMID:20301662
        reference_title: "X-Linked Dystonia-Parkinsonism."
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: "Anticholinergic agents, benzodiazepines, and sometimes neuroleptics are used in the early stages of dystonia"
        explanation: GeneReviews recommends anticholinergic agents for early-stage dystonia.
  - name: Tetrabenazine and zolpidem
    description: >
      Zolpidem and tetrabenazine are used after dystonia becomes multifocal or
      generalized.
    therapeutic_modality: SMALL_MOLECULE
    treatment_term:
      preferred_term: pharmacotherapy
      term:
        id: MAXO:0000058
        label: pharmacotherapy
      therapeutic_agent:
        - preferred_term: tetrabenazine
          term:
            id: CHEBI:9467
            label: tetrabenazine
        - preferred_term: zolpidem
          term:
            id: CHEBI:10125
            label: zolpidem
    target_phenotypes:
      - preferred_term: Generalized dystonia
        term:
          id: HP:0007325
          label: Generalized dystonia
    evidence:
      - reference: PMID:20301662
        reference_title: "X-Linked Dystonia-Parkinsonism."
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: "zolpidem and tetrabenazine are used after dystonia becomes multifocal or generalized"
        explanation: GeneReviews recommends zolpidem and tetrabenazine for multifocal/generalized dystonia.
  - name: Botulinum toxin injection
    description: >
      Botulinum toxin injections improve focal dystonia but may worsen
      swallowing in individuals with preexisting dysphagia.
    therapeutic_modality: OTHER
    treatment_term:
      preferred_term: botulinum toxin type A therapy
      term:
        id: MAXO:0009016
        label: botulinum toxin type A therapy
    target_phenotypes:
      - preferred_term: Oromandibular dystonia
        term:
          id: HP:0012048
          label: Oromandibular dystonia
    evidence:
      - reference: PMID:20301662
        reference_title: "X-Linked Dystonia-Parkinsonism."
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: "Botulinum toxin injections improve focal dystonia but may worsen swallowing in individuals with preexisting dysphagia."
        explanation: GeneReviews documents botulinum toxin for focal dystonia and its dysphagia caution.
  - name: Levodopa and dopamine agonists
    description: >
      Parkinsonism in XDP is treated with levodopa and dopamine agonists to
      control tremor.
    therapeutic_modality: SMALL_MOLECULE
    treatment_term:
      preferred_term: pharmacotherapy
      term:
        id: MAXO:0000058
        label: pharmacotherapy
      therapeutic_agent:
        - preferred_term: levodopa
          term:
            id: CHEBI:15765
            label: L-dopa
    target_phenotypes:
      - preferred_term: Parkinsonism
        term:
          id: HP:0001300
          label: Parkinsonism
    evidence:
      - reference: PMID:20301662
        reference_title: "X-Linked Dystonia-Parkinsonism."
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: "Parkinsonism is treated with levodopa and dopamine agonists to control tremor."
        explanation: GeneReviews recommends levodopa and dopamine agonists for XDP parkinsonism.
  - name: Bilateral pallidal deep brain stimulation
    description: >
      Bilateral pallidal deep brain stimulation may be used to treat advanced
      disease and medically refractory dystonia, although it may have less
      effect on parkinsonism. In patients with combined dystonia and
      parkinsonism, pallidal DBS has produced rapid improvement of hyperkinetic
      movements, but effects on hypokinetic features have been inconsistent.
    therapeutic_modality: DEVICE
    treatment_term:
      preferred_term: deep brain stimulation
      term:
        id: MAXO:0000943
        label: deep brain stimulation
    target_phenotypes:
      - preferred_term: Generalized dystonia
        term:
          id: HP:0007325
          label: Generalized dystonia
    evidence:
      - reference: PMID:20301662
        reference_title: "X-Linked Dystonia-Parkinsonism."
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: "Bilateral pallidal deep brain stimulation may be used to treat advanced disease and medically refractory dystonia, although it may have less effect on parkinsonism."
        explanation: GeneReviews documents pallidal DBS for advanced/refractory dystonia.
      - reference: PMID:31116117
        reference_title: "X-Linked Dystonia-Parkinsonism: recent advances."
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: "In patients exhibiting features of both dystonia and parkinsonism, pallidal DBS has resulted in rapid improvement of hyperkinetic movements, but effects on hypokinetic features have been inconsistent."
        explanation: Confirms DBS benefit for hyperkinetic (dystonic) features with inconsistent effect on parkinsonism.

mechanistic_hypotheses:
  - hypothesis_group_id: g4_transcriptional_interference
    hypothesis_label: G-quadruplex-mediated transcriptional interference at the XDP SVA
    status: EMERGING
    description: >
      The G-rich (CCCTCT)n hexameric repeat within the XDP SVA folds into stable
      G-quadruplex (G4) structures that interfere with TAF1 transcription.
      Pharmacologic stabilization of these G4s reduces TAF1 transcripts while
      destabilization (unfolding) increases TAF1 transcripts, implicating G4
      formation as a major cause of aberrant TAF1 expression and a candidate
      therapeutic target.
    evidence:
      - reference: PMID:39287133
        reference_title: "G-quadruplexes in an SVA retrotransposon cause aberrant TAF1 gene expression in X-linked dystonia parkinsonism."
        supports: SUPPORT
        evidence_source: IN_VITRO
        snippet: "Our data indicate that G4 formation in the XDP SVA is a major cause of aberrant TAF1 expression"
        explanation: Establishes G-quadruplex formation in the XDP SVA as a major driver of aberrant TAF1 expression.
      - reference: PMID:39287133
        reference_title: "G-quadruplexes in an SVA retrotransposon cause aberrant TAF1 gene expression in X-linked dystonia parkinsonism."
        supports: SUPPORT
        evidence_source: IN_VITRO
        snippet: "stabilisation of the XDP SVA G4s reduces TAF1 transcripts downstream and around the SVA, and increases upstream transcripts, while destabilisation using the G4 unfolder PhpC increases TAF1 transcripts"
        explanation: Demonstrates bidirectional pharmacologic modulation of TAF1 transcription by G4 ligands, supporting G4s as a causal and druggable mechanism.
  - hypothesis_group_id: sva_epigenetic_repression
    hypothesis_label: ZNF91-dependent mini-heterochromatin constrains the XDP SVA
    status: EMERGING
    description: >
      An innate epigenetic defense system mediated by the KRAB zinc-finger
      protein ZNF91 deposits H3K9me3 and DNA methylation over SVA elements,
      forming mini-heterochromatin domains that attenuate the cis-regulatory
      impact of the XDP SVA. Loss of this local heterochromatin worsens the XDP
      molecular phenotype, increasing TAF1 intron retention and reducing TAF1
      expression.
    evidence:
      - reference: PMID:38834915
        reference_title: "Mini-heterochromatin domains constrain the cis-regulatory impact of SVA transposons in human brain development and disease."
        supports: SUPPORT
        evidence_source: IN_VITRO
        snippet: "the KRAB zinc finger protein ZNF91 establishes H3K9me3 and DNA methylation over SVAs"
        explanation: Identifies ZNF91-mediated heterochromatin as the epigenetic control system over SVA elements.
      - reference: PMID:38834915
        reference_title: "Mini-heterochromatin domains constrain the cis-regulatory impact of SVA transposons in human brain development and disease."
        supports: SUPPORT
        evidence_source: IN_VITRO
        snippet: "removal of local heterochromatin severely aggravates the XDP molecular phenotype, resulting in increased TAF1 intron retention and reduced expression"
        explanation: Shows that loss of SVA heterochromatin worsens TAF1 intron retention and reduces expression, linking epigenetic repression to the XDP molecular phenotype.

clinical_trials:
  - name: NCT05592028
    description: >
      Bilateral transcranial magnetic resonance-guided focused ultrasound
      (MRgFUS) pallidothalamic tractotomy for patients with genetically
      confirmed X-linked dystonia-parkinsonism, conducted at the Philippine
      General Hospital. The primary outcome is change in the XDP-Movement
      Disorder Society of the Philippines Scale; secondary measures include the
      Burke-Fahn-Marsden Dystonia Rating Scale and MDS-UPDRS Part III.
    target_phenotypes:
      - preferred_term: Dystonia
        term:
          id: HP:0001332
          label: Dystonia
      - preferred_term: Parkinsonism
        term:
          id: HP:0001300
          label: Parkinsonism
    evidence:
      - reference: PMID:37596524
        reference_title: "Transcranial magnetic resonance-guided focused ultrasound pallidothalamic tractotomy for patients with X-linked dystonia-parkinsonism: a study protocol."
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: "This study aims to determine the improvement in dystonia and parkinsonism in patients with XDP after MRgFUS pallidothalamic tractotomy."
        explanation: The registered protocol (NCT05592028) evaluates MRgFUS pallidothalamic tractotomy for dystonia and parkinsonism in XDP.

📚

References & Deep Research

References

1

PMID:20301662

X-Linked Dystonia-Parkinsonism.

No top-level findings curated for this source.

Deep Research

1

Falcon ▸

X-linked Dystonia–Parkinsonism (XDP; “Lubag”) — Comprehensive Disease Characteristics Report

Edison Scientific Literature 30 citations 2026-06-03T15:29:23.171821

X-linked Dystonia–Parkinsonism (XDP; “Lubag”) — Comprehensive Disease Characteristics Report

Target disease

Disease: X-linked dystonia–parkinsonism (XDP)
Category: Mendelian; X-linked (recessive) movement disorder
Key synonym set: DYT3; DYT/PARK-TAF1; “Lubag” (pozojevic2022xlinkeddystoniaparkinsonismover pages 1-2, pozojevic2022factorsinfluencingreduced pages 1-2)

Executive summary (current understanding)

XDP is an adult-onset, progressive neurodegenerative movement disorder with a strong founder effect in individuals of Filipino ancestry, especially from Panay Island in the Philippines. Clinically, it most often begins as focal dystonia that generalizes over several years and later evolves toward combined dystonia–parkinsonism and then a parkinsonian-predominant phase in surviving patients. The causal variant is a founder SINE–VNTR–Alu (SVA) retrotransposon insertion in TAF1 intron 32 that disrupts TAF1 transcription and RNA processing; a polymorphic intronic (CCCTCT)n hexamer repeat within the SVA strongly modifies age at onset and shows tissue-specific somatic instability. Recent 2024 work provides mechanistic detail implicating (i) G-quadruplex formation within the amplified repeat domain and (ii) an innate epigenetic defense mediated by the KRAB zinc-finger protein ZNF91 that deposits H3K9me3/DNA methylation (“mini-heterochromatin”) over SVAs and modulates the XDP molecular phenotype. (nicoletto2024gquadruplexesinan pages 1-2, horvath2024miniheterochromatindomainsconstrain pages 1-2)

1. Disease information

1.1 What is the disease?

XDP is an adult-onset neurodegenerative movement disorder characterized by dystonia and parkinsonism, endemic to the Philippines with strong association to Panay Island and Filipino ancestry. It is X-linked and predominantly affects males. (jamora2023transcranialmagneticresonanceguided pages 1-2, pozojevic2022xlinkeddystoniaparkinsonismover pages 1-2)

1.2 Key identifiers

OMIM: 314250 (XDP; DYT/PARK-TAF1) (pozojevic2022xlinkeddystoniaparkinsonismover pages 1-2, campion2022tissuespecificandrepeat pages 1-2)
Other IDs (Orphanet, MeSH, MONDO, ICD-10/ICD-11): Not found in the retrieved, tool-accessible corpus; these should be added from OMIM/Orphanet/MONDO cross-references during curation.

1.3 Synonyms / alternative names

X-linked dystonia–parkinsonism (XDP)
DYT3
DYT/PARK-TAF1
Lubag
(pozojevic2022xlinkeddystoniaparkinsonismover pages 1-2, pozojevic2022factorsinfluencingreduced pages 1-2)

1.4 Evidence type note

The information synthesized here is derived from aggregated disease-level reviews and primary human studies, including patient-derived cell models, postmortem references, and clinical study protocols/registries. (nicoletto2024gquadruplexesinan pages 1-2, tshilenge2024proteomicanalysisof pages 1-2, jamora2023transcranialmagneticresonanceguided pages 1-2)

2. Etiology

2.1 Primary causal factors (genetic)

Causal locus and structural variant - XDP is caused by a founder SVA retrotransposon insertion in intron 32 of TAF1, with associated disruption of TAF1 RNA processing and expression. (tshilenge2024proteomicanalysisof pages 1-2, crombie2024therolesof pages 13-14)

Repeat feature within the SVA - The pathogenic SVA contains a polymorphic (CCCTCT)n hexameric repeat (often reported in the ~30–55 range), which correlates with disease expressivity/age at onset and is somatically unstable. (crombie2024therolesof pages 11-13, campion2022tissuespecificandrepeat pages 1-2)

2.2 Risk factors

Genetic: Carrying the XDP founder haplotype/TAF1 intron 32 SVA insertion is the primary determinant (Mendelian). (tshilenge2024proteomicanalysisof pages 1-2)
Sex: Male predominance due to X-linked inheritance; ~95% male in one summary/protocol context. (jamora2023transcranialmagneticresonanceguided pages 1-2)
Repeat length: Longer (CCCTCT)n repeat is associated with earlier onset; additionally, somatic expansion is implicated as a disease driver. (campion2022tissuespecificandrepeat pages 1-2, pozojevic2022xlinkeddystoniaparkinsonismover pages 2-4)

2.3 Protective factors

No validated protective environmental or pharmacologic factors were identified in the retrieved evidence. Genetic “protective” alleles are implied via modifier loci (e.g., MSH3/PMS2) that delay onset. (pozojevic2022xlinkeddystoniaparkinsonismover pages 2-4, campion2022tissuespecificandrepeat pages 1-2)

2.4 Gene–environment interactions

No specific gene–environment interaction evidence was found in the retrieved corpus.

3. Phenotypes

3.1 Core phenotype spectrum (with suggested HPO terms)

Dystonia (dominant early feature) - Typical presentation: focal dystonia that often generalizes within ~2–5 years. (pozojevic2022factorsinfluencingreduced pages 1-2, jamora2023transcranialmagneticresonanceguided pages 1-2) - Suggested HPO terms: Dystonia (HP:0001332); Focal dystonia (HP:0004370); Generalized dystonia (HP:0007256); Segmental dystonia (HP:0002540).

Distribution/frequencies (useful for knowledge base) - Craniocervical onset ~60%; limb onset ~37%; truncal ~4%. (pozojevic2022factorsinfluencingreduced pages 1-2) - Blepharospasm ~28%; mouth/tongue dystonia ~23%. (pozojevic2022factorsinfluencingreduced pages 1-2) - Suggested HPO terms: Cervical dystonia (HP:0001333); Blepharospasm (HP:0000520); Oromandibular dystonia (HP:0000180); Limb dystonia (HP:0002456); Truncal dystonia (HP:0002547).

Parkinsonism (often later; sometimes initial) - Parkinsonism can present initially (~14% in one summary) or typically emerges later, often beyond the ~10th year, with tremor, bradykinesia, and gait instability. (pozojevic2022factorsinfluencingreduced pages 1-2, jamora2023transcranialmagneticresonanceguided pages 1-2) - Suggested HPO terms: Parkinsonism (HP:0001300); Bradykinesia (HP:0002067); Gait instability (HP:0002317); Tremor (HP:0001337).

3.2 Age of onset / severity / progression

Typical onset: mean/median ~39–40 years; range reported 20–67 years in genetically confirmed series (and other series reporting broader ranges). (pozojevic2022factorsinfluencingreduced pages 1-2, jamora2023transcranialmagneticresonanceguided pages 1-2)
Progression: focal dystonia → generalized dystonia → combined dystonia–parkinsonism → parkinsonian predominance in survivors. (pozojevic2022factorsinfluencingreduced pages 1-2)

3.3 Quality of life impact

XDP is associated with poor quality of life and decreased life expectancy; the MRgFUS study protocol includes EQ-5D-5L as a QoL metric, reflecting clinical emphasis on functional impact. (jamora2023transcranialmagneticresonanceguided pages 1-2)

4. Genetic / molecular information

4.1 Causal gene(s)

TAF1 (TATA-binding protein associated factor 1), Xq13.1; disease mechanism arises from a noncoding structural variant (SVA insertion) in intron 32 that perturbs transcription and RNA processing. (crombie2024therolesof pages 1-2, tshilenge2024proteomicanalysisof pages 1-2)

4.2 Pathogenic variant type/class

Structural variant / mobile element insertion: SVA retrotransposon insertion in TAF1 intron 32. (tshilenge2024proteomicanalysisof pages 1-2)
Embedded repeat: polymorphic (CCCTCT)n repeat tract within SVA; variable length and unstable. (campion2022tissuespecificandrepeat pages 1-2)

4.3 Modifier genes

DNA mismatch repair genes MSH3 and PMS2 are reported modifiers of age-related penetrance/age at onset, linking XDP to somatic repeat instability biology. (pozojevic2022xlinkeddystoniaparkinsonismover pages 2-4, campion2022tissuespecificandrepeat pages 1-2)

4.4 Epigenetic information

Multiple lines of evidence indicate epigenetic regulation at/around the SVA influences the molecular phenotype, including heterochromatin-based repression of SVAs (ZNF91-driven) and disease-related chromatin changes reversible by SVA excision in model systems. (horvath2024miniheterochromatindomainsconstrain pages 1-2, crombie2024therolesof pages 13-14)

5. Environmental information

No specific toxins, lifestyle factors, or infectious triggers were supported by retrieved evidence as contributors to XDP risk or progression.

6. Mechanism / pathophysiology

6.1 Causal chain (from variant to phenotype)

Upstream lesion: Founder SVA insertion (with amplified (CCCTCT)n repeat) in TAF1 intron 32 (tshilenge2024proteomicanalysisof pages 1-2).

Intermediate molecular effects (RNA + chromatin + transcription) 1) Aberrant TAF1 RNA processing: altered splicing with partial intron 32 retention and decreased transcription downstream of the insertion is repeatedly described across XDP neural models. (tshilenge2024proteomicanalysisof pages 1-2) 2) Cryptic exon/aberrant transcript: a disease-associated intronic exon (“32i”) produces TAF1−32i, disrupting the ORF and linked to premature termination/NMD in review synthesis. (crombie2024therolesof pages 13-14) 3) G-quadruplex mechanism (2024 primary advance): Nicoletto et al. (Nucleic Acids Research; advance access 17 Sep 2024; https://doi.org/10.1093/nar/gkae797) report that stable G4s form at the XDP SVA and modulate TAF1 transcription. Abstract quote: “Our data indicate that G4 formation in the XDP SVA is a major cause of aberrant TAF1 expression.” (nicoletto2024gquadruplexesinan pages 1-2) 4) Epigenetic repression / innate defense (2024 primary advance): Horváth et al. (Nature Structural & Molecular Biology; accepted 17 Apr 2024; https://doi.org/10.1038/s41594-024-01320-8) show ZNF91 establishes H3K9me3 and DNA methylation over SVAs; “removal of local heterochromatin severely aggravates the XDP molecular phenotype, resulting in increased TAF1 intron retention and reduced expression.” (horvath2024miniheterochromatindomainsconstrain pages 1-2) 5) Age-related modulation (2024): Rosenkrantz et al. (PNAS; published 5 Aug 2024; https://doi.org/10.1073/pnas.2401217121) report ZNF91 binds G4-prone DNA and propose age-related decline in ZNF91 may contribute to late onset; the paper describes ZNF91 binding to DNA with “high G4 propensity” and hypothesizes ZNF91 “binds to and prevents the formation of G4s…within the XDP-SVA.” (rosenkrantz2024znf91isan pages 1-2)

Downstream cellular/tissue pathology - Preferential vulnerability/degeneration of striatal medium spiny neurons (MSNs) and striatal atrophy (caudate/putamen). (tshilenge2024proteomicanalysisof pages 1-2, crombie2024therolesof pages 13-14) - Proteomics (2024) indicates broad dysregulation of RNA metabolism/splicing, mitochondrial function, chromatin assembly, and neurodegeneration-related pathways in patient-derived MSNs. (tshilenge2024proteomicanalysisof pages 1-2)

6.2 Molecular pathways and processes (suggested GO terms)

Representative GO biological process terms to support annotation (based on evidence above): - Regulation of transcription by RNA polymerase II; transcription initiation by RNA polymerase II (tshilenge2024proteomicanalysisof pages 2-4) - mRNA processing; RNA splicing; intron retention (tshilenge2024proteomicanalysisof pages 1-2, horvath2024miniheterochromatindomainsconstrain pages 1-2) - Nonsense-mediated mRNA decay (NMD) (crombie2024therolesof pages 13-14) - Chromatin-mediated transcriptional repression; establishment of H3K9 methylation; DNA methylation (horvath2024miniheterochromatindomainsconstrain pages 1-2) - Mitochondrial function / mitochondrial disassembly (tshilenge2024proteomicanalysisof pages 1-2)

6.3 Cell types (suggested CL terms)

Medium spiny neuron (striatal projection neuron; GABAergic) (tshilenge2024proteomicanalysisof pages 1-2)
Neural stem cell; neural progenitor cell (NPC) (tshilenge2024proteomicanalysisof pages 1-2, horvath2024miniheterochromatindomainsconstrain pages 1-2)

6.4 Anatomical structures (suggested UBERON terms)

Striatum; caudate nucleus; putamen; basal ganglia (crombie2024therolesof pages 13-14)
Additional regions implicated in summaries: cerebral cortex, substantia nigra, cerebellum (campion2022tissuespecificandrepeat pages 1-2, tshilenge2024proteomicanalysisof pages 1-2)

6.5 Visual evidence (locus + intron retention)

Figure evidence from Horváth et al. shows the TAF1 locus with the XDP SVA insertion and RNA-seq tracks illustrating intron 32 retention in XDP NPC models. (horvath2024miniheterochromatindomainsconstrain media 7af698dd)

7. Anatomical structures affected

Primary system: nervous system (motor control circuits). (pozojevic2022xlinkeddystoniaparkinsonismover pages 1-2)
Primary structures: striatum (caudate/putamen) with preferential MSN degeneration. (tshilenge2024proteomicanalysisof pages 1-2)
Additional involvement: cortex, substantia nigra, cerebellum referenced in disease context and pathology discussions. (campion2022tissuespecificandrepeat pages 1-2, tshilenge2024proteomicanalysisof pages 1-2)

8. Temporal development

Onset: adult (mean ~39–40 years; range commonly cited 20–67 in genetically confirmed series). (pozojevic2022factorsinfluencingreduced pages 1-2, jamora2023transcranialmagneticresonanceguided pages 1-2)
Progression: generalization of dystonia within 2–5 years; parkinsonism typically beyond ~10 years. (jamora2023transcranialmagneticresonanceguided pages 1-2)

9. Inheritance and population

Inheritance: X-linked recessive; male predominance; rare affected females via homozygosity or skewed X-inactivation/aneuploidy described in reviews. (pozojevic2022factorsinfluencingreduced pages 1-2, crombie2024therolesof pages 14-16)
Epidemiology: prevalence ~5.74/100,000 on Panay; also reported 0.31/100,000 in the Philippines overall. (jamora2023transcranialmagneticresonanceguided pages 1-2)
Population demography: predominantly Filipino ancestry; founder effect. (pozojevic2022xlinkeddystoniaparkinsonismover pages 1-2)

10. Diagnostics

10.1 Clinical diagnosis

Suspect XDP in adult-onset focal-to-generalized dystonia with evolving parkinsonism in individuals with Filipino/Panay ancestry or relevant family history. (jamora2023transcranialmagneticresonanceguided pages 1-2)

10.2 Genetic testing (confirmatory)

Confirmatory testing targets the TAF1 intron 32 SVA insertion / founder haplotype. This is operationalized in clinical protocols requiring “genetically confirmed XDP” for enrollment. (NCT05592028 chunk 1, jamora2023transcranialmagneticresonanceguided pages 1-2)

10.3 Molecular/omics assays used in recent research (informing diagnostic biomarker development)

RNA-seq/Capture RNA-seq to quantify intron 32 retention / aberrant TAF1 isoforms (tshilenge2024proteomicanalysisof pages 1-2)
Anti-G4 ChIP-seq/qPCR to detect folded G-quadruplexes at XDP SVA in patient cells (nicoletto2024gquadruplexesinan pages 1-2)
Chromatin profiling (H3K9me3, DNA methylation) in NPC models to assess SVA repression (horvath2024miniheterochromatindomainsconstrain pages 1-2)

10.4 Differential diagnosis

Differential diagnosis content (distinguishing from other dystonia-parkinsonism syndromes) was not comprehensively retrievable from the current evidence set.

11. Outcome / prognosis

Mean duration of illness: ~16 years (jamora2023transcranialmagneticresonanceguided pages 1-2)
Mean age of death: ~55.6 years (jamora2023transcranialmagneticresonanceguided pages 1-2)
Major complications/causes of death: aspiration (aspiration pneumonia), starvation/weight loss, and suicide are cited as contributors to shortened lifespan; many do not survive >10 years after onset in one summary. (pozojevic2022factorsinfluencingreduced pages 1-2)

12. Treatment

12.1 Symptomatic pharmacotherapy and chemodenervation (real-world practice)

Jamora et al. (BMC Neurology; Aug 2023; https://doi.org/10.1186/s12883-023-03344-x) list oral medications used symptomatically (e.g., carbidopa/levodopa, trihexyphenidyl, biperiden, haloperidol, diazepam, zolpidem, milacemide, anticonvulsants, antihistamines), noting variable/suboptimal response. Botulinum toxin A and muscle afferent blockade are also used. (jamora2023transcranialmagneticresonanceguided pages 1-2)

Suggested MAXO terms (examples): pharmacotherapy; levodopa therapy; anticholinergic therapy; benzodiazepine therapy; botulinum toxin injection; supportive care.

12.2 Deep brain stimulation (DBS)

DBS has been reported as “immediately effective and robust” for alleviating debilitating XDP symptoms, but is costly and often unaffordable in endemic settings. (jamora2023transcranialmagneticresonanceguided pages 2-4)

Suggested MAXO term: deep brain stimulation.

12.3 Ablative and incisionless interventions: MR-guided focused ultrasound (MRgFUS)

Rationale and protocolized implementation (2023–ongoing): - Jamora et al. describe a prospective MRgFUS pallidothalamic tractotomy protocol at Philippine General Hospital using XDP-MDSP as primary outcome and BFMDRS + MDS-UPDRS Part III as additional measures; the protocol is registered as NCT05592028 and includes EQ-5D-5L and MoCA. (jamora2023transcranialmagneticresonanceguided pages 1-2, NCT05592028 chunk 1)

Clinical outcomes (small series): - Four genetically confirmed Filipino XDP patients treated with MRgFUS pallidothalamic tract lesioning reported ~30–36% improvement in XDP-MDSP scores at 6 months and 1 year (as summarized in the protocol paper). (jamora2023transcranialmagneticresonanceguided pages 1-2)

Suggested MAXO terms: MR-guided focused ultrasound ablation; pallidothalamic tractotomy.

12.4 Experimental / precision-medicine directions (preclinical)

Recent mechanistic work suggests several therapeutic hypotheses: - Targeting G-quadruplex structures to restore TAF1 transcriptional output (nicoletto2024gquadruplexesinan pages 1-2) - Modulating SVA repression pathways (ZNF91/heterochromatin) (horvath2024miniheterochromatindomainsconstrain pages 1-2) - Correcting aberrant splicing and/or directly excising the SVA (CRISPR rescue in model systems cited in reviews/primary summaries) (pozojevic2022xlinkeddystoniaparkinsonismover pages 2-4, crombie2024therolesof pages 13-14)

13. Prevention

Primary prevention: Not established.
Secondary prevention: Potential future direction is identification of prodromal molecular/physiologic markers (e.g., intron-retention signatures), but not validated for routine screening in retrieved evidence. (crombie2024therolesof pages 13-14)
Genetic counseling: Implied as central preventive action (family planning, cascade testing) given X-linked inheritance and documented affected females via special mechanisms. (pozojevic2022factorsinfluencingreduced pages 1-2, crombie2024therolesof pages 14-16)

14. Other species / natural disease

No naturally occurring XDP-like disease in non-human species was identified in the retrieved evidence.

15. Model organisms / model systems

15.1 Human cellular models (high relevance)

iPSC-derived neural stem cells and iPSC-derived medium spiny neurons used for quantitative proteomics and TAF1 splicing/intron retention observations. (tshilenge2024proteomicanalysisof pages 1-2)
Human neural progenitor cell (NPC) models used for epigenetic regulation of SVAs and XDP molecular phenotype modulation. (horvath2024miniheterochromatindomainsconstrain pages 1-2)
Patient-derived fibroblasts and NPCs used to demonstrate G4 folding at the SVA and to modulate TAF1 transcription using G4 ligands/unfolders. (nicoletto2024gquadruplexesinan pages 1-2)

15.2 Non-human models

A mouse knockdown model affecting nTaf1 is mentioned in review-level synthesis as producing motor defects, but detailed model phenotyping was not available in the retrieved evidence set. (crombie2024therolesof pages 11-13)

Recent developments (prioritizing 2023–2024)

1) G-quadruplex-driven transcriptional dysregulation: Nucleic Acids Research (Sept 2024) provides experimental evidence that stable G4s form within the XDP SVA in patient cells and that pharmacologic stabilization/destabilization shifts TAF1 transcript patterns. (nicoletto2024gquadruplexesinan pages 1-2) 2) Innate epigenetic defense against SVAs: Nature Structural & Molecular Biology (June 2024) shows ZNF91-dependent mini-heterochromatin (H3K9me3 + DNA methylation) constrains SVA cis-regulatory effects and that loss of local heterochromatin worsens TAF1 intron retention/expression in XDP NPCs. (horvath2024miniheterochromatindomainsconstrain pages 1-2) 3) Proteome-level signatures in striatal neurons: Neurobiology of Disease (Jan 2024) describes pathway enrichments implicating RNA metabolism/splicing and mitochondrial/chromatin processes in patient-derived MSNs, reinforcing RNA-processing as a central disease axis. (tshilenge2024proteomicanalysisof pages 1-2) 4) Clinical translation efforts in endemic regions: BMC Neurology (Aug 2023) protocol and ClinicalTrials.gov expanded-access listing reflect real-world implementation of MRgFUS pallidothalamic tractotomy with XDP-specific outcome measures. (jamora2023transcranialmagneticresonanceguided pages 1-2, NCT05592028 chunk 1)

Current applications / real-world implementations

Symptomatic oral pharmacotherapy and botulinum toxin are used clinically, with variable response. (jamora2023transcranialmagneticresonanceguided pages 1-2)
Surgical/lesional interventions: DBS is effective but costly; MRgFUS is being developed as a potentially more accessible incisionless alternative, with protocols deployed in the Philippines and small series experience. (jamora2023transcranialmagneticresonanceguided pages 2-4, jamora2023transcranialmagneticresonanceguided pages 1-2)

Clinical trials and registries (URLs + key metadata)

NCT05592028 (Expanded Access; AVAILABLE): “High Intensity Focused Ultrasound for X-linked Dystonia-parkinsonism” (MRgFUS pallidothalamic tractotomy; PGH, Philippines). Outcomes include XDP-MDSP, XDP staging, BFMDRS, UPDRS with follow-up through 12 months. (NCT05592028 chunk 1)
NCT03019458 (Completed; 50 participants): “MINGO Supplemental Trial in X-linked Dystonia-Parkinsonism Patients” (nutritional supplement; BMI primary endpoint; Roxas City, Philippines). (NCT03019458 chunk 1)
NCT05713721 (Observational; includes DYT/PARK-TAF1 arm): sensorimotor integration study including DBS on/off evaluation in symptomatic carriers; neurophysiology via TMS short-latency afferent inhibition and blinded video ratings. (NCT05713721 chunk 2)

Statistics and data highlights (human studies)

Prevalence: Panay ~5.74/100,000; Philippines ~0.31/100,000 (jamora2023transcranialmagneticresonanceguided pages 1-2)
Sex distribution: ~95% male in one report (jamora2023transcranialmagneticresonanceguided pages 1-2)
Age at onset: ~39–40 years typical; ranges reported 20–67 (and other reports 12–64) (pozojevic2022factorsinfluencingreduced pages 1-2, campion2022tissuespecificandrepeat pages 1-2)
Clinical progression: generalization within ~2–5 years (jamora2023transcranialmagneticresonanceguided pages 1-2)
Outcome: mean duration ~16 years; mean age of death ~55.6 years (jamora2023transcranialmagneticresonanceguided pages 1-2)
Phenotype frequencies: craniocervical onset ~60%, limb ~37%, truncal ~4%; blepharospasm 28%; mouth/tongue dystonia 23% (pozojevic2022factorsinfluencingreduced pages 1-2)

Structured summary table

Domain	Key facts	Evidence type	Key citations
Identifiers	X-linked dystonia-parkinsonism (XDP); synonyms: DYT/PARK-TAF1, DYT3, Lubag; OMIM #314250; adult-onset X-linked neurodegenerative movement disorder, endemic in the Philippines/Panay founder population	Review	(pozojevic2022factorsinfluencingreduced pages 1-2, pozojevic2022xlinkeddystoniaparkinsonismover pages 1-2)
Genetics	Causal lesion is a ~2.6 kb SINE-VNTR-Alu (SVA) retrotransposon inserted in intron 32 of TAF1 on Xq13.1; all probands share a founder haplotype around TAF1; CRISPR excision of the SVA restores TAF1 mRNA in model cells	Review + primary	(pozojevic2022xlinkeddystoniaparkinsonismover pages 1-2, crombie2024therolesof pages 1-2, pozojevic2022xlinkeddystoniaparkinsonismover pages 2-4)
Repeat feature	The pathogenic SVA contains a polymorphic hexameric (CCCTCT)n repeat; typical reported range ~30–55 repeats, with amplified HEX tract compared with typical SVAs; repeat length inversely correlates with age at onset and age at death	Review + primary	(nicoletto2024gquadruplexesinan pages 1-2, campion2022tissuespecificandrepeat pages 1-2, crombie2024therolesof pages 11-13, pozojevic2022xlinkeddystoniaparkinsonismover pages 2-4)
Modifiers	Each additional hexamer repeat shortens age at onset by ~1.4 years in larger cohorts; repeat length explained ~50% of age-at-onset variance initially, and repeat plus known modifiers explain only ~65%, implying additional factors	Review	(pozojevic2022xlinkeddystoniaparkinsonismover pages 4-5)
DNA repair modifiers	MSH3 and PMS2 modify age-associated penetrance/expressivity; protective alleles delay onset; findings link XDP to repeat-instability biology shared with Huntington disease	Review + primary	(pozojevic2022factorsinfluencingreduced pages 1-2, campion2022tissuespecificandrepeat pages 1-2, crombie2024therolesof pages 14-16, pozojevic2022xlinkeddystoniaparkinsonismover pages 2-4)
Inheritance / penetrance	X-linked recessive; predominantly affects Filipino males; rare affected females occur via homozygosity, skewed X-inactivation, or aneuploidy; penetrance is age-dependent	Review	(pozojevic2022factorsinfluencingreduced pages 1-2, crombie2024therolesof pages 14-16)
Epidemiology	Endemic on Panay island, Philippines; reported prevalence ~5.74 per 100,000 in Panay; strong founder effect with indigenous Philippine haplotype	Review + primary summary	(pozojevic2022xlinkeddystoniaparkinsonismover pages 1-2, tshilenge2024proteomicanalysisof pages 1-2)
Age at onset	Median/average onset ~39–40 years; reported onset range 20–67 years; disease is chronic, progressive, and fatal	Review + primary	(pozojevic2022factorsinfluencingreduced pages 1-2, campion2022tissuespecificandrepeat pages 1-2, crombie2024therolesof pages 11-13)
Core clinical phenotype	>80% present with focal dystonia; dystonia is initial feature in ~93% in some series; onset distribution ~60% craniocervical, ~37% limb, ~4% truncal; dystonia typically generalizes within 5 years (5–10 years in some reviews), then parkinsonism may emerge and later predominate	Review	(pozojevic2022factorsinfluencingreduced pages 1-2, pozojevic2022xlinkeddystoniaparkinsonismover pages 1-2, crombie2024therolesof pages 11-13)
Morbidity / outcome	Severe disability is common; aspiration contributes to premature death; mean age at death reported ~55.6 years; no obvious correlation between repeat length and disease duration in one primary study	Review + primary	(pozojevic2022xlinkeddystoniaparkinsonismover pages 1-2, campion2022tissuespecificandrepeat pages 1-2, crombie2024therolesof pages 11-13)
Neuropathology	Preferential degeneration of striatal medium spiny neurons with caudate/putaminal atrophy; iron accumulation in anteromedial putamen reported; subventricular zone neural progenitor loss also described	Review + primary/review	(pozojevic2022xlinkeddystoniaparkinsonismover pages 1-2, crombie2024therolesof pages 11-13, tshilenge2024proteomicanalysisof pages 1-2)
Molecular mechanism: TAF1	XDP SVA is associated with reduced/aberrant TAF1 expression, altered splicing, partial intron 32 retention, and disease-associated transcript TAF1-32i from cryptic exon 32i that disrupts the ORF and can trigger nonsense-mediated decay	Review + primary	(tshilenge2024proteomicanalysisof pages 1-2, crombie2024therolesof pages 13-14)
Mechanism: G-quadruplexes	G-rich XDP SVA sequences form stable G-quadruplexes in vitro and in patient fibroblasts/NPCs; G4 stabilization (BRACO-19, quarfloxin) reduces downstream TAF1 transcripts and increases upstream transcripts, while G4 destabilization (PhpC) increases TAF1 transcripts	Primary	(nicoletto2024gquadruplexesinan pages 1-2)
Mechanism: epigenetic repression	ZNF91 binds SVAs and, with TRIM28, helps establish local mini-heterochromatin marked by H3K9me3 and DNA methylation; removing this repression worsens the XDP molecular phenotype, increasing TAF1 intron retention and reducing TAF1 expression	Primary	(horvath2024miniheterochromatindomainsconstrain pages 10-11, horvath2024miniheterochromatindomainsconstrain pages 1-2)
Mechanism: aging modifier	ZNF91 expression declines with age in brain/blood; reported associations include frontal cortex dR2 = -0.10354 (P = 2.02E-06), cerebellum dR2 = -0.0484 (P = 5.79E-04), nucleus accumbens dR2 = -0.05257 (P = 0.0003); this may help explain late onset	Primary	(rosenkrantz2024znf91isan pages 8-9, rosenkrantz2024znf91isan pages 7-8)
Somatic instability	Repeat instability is expansion-biased, length-dependent, and tissue-specific; brain shows greater expansion than blood; cortical regions show relatively high instability, cerebellum low instability; observed changes range from small shifts (up to ±5 repeats) to rarer large expansions (~20 to >100 repeats) and contractions (~20–40 repeats)	Primary	(campion2022tissuespecificandrepeat pages 1-2)
Molecular profiling	Proteomics in patient-derived striatal neurons/MSNs shows altered RNA metabolism, splicing, mitochondrial pathways, chromatin assembly, and overlap with neurodegeneration networks; TAF1, YY1, ATF2, USF1, and MYC emerged as enriched regulators	Primary	(tshilenge2024proteomicanalysisof pages 1-2)
Biomarkers	Disease-specific TAF1 intron-retention / TAF1-32i transcripts are candidate molecular biomarkers; reviews also cite neurofilament light chain as a proposed biomarker direction, but validated clinical biomarker use remains limited	Review + primary	(crombie2024therolesof pages 13-14, pozojevic2022xlinkeddystoniaparkinsonismover pages 2-4, pozojevic2022xlinkeddystoniaparkinsonismover pages 1-2)
Diagnostics	Diagnosis integrates characteristic phenotype, Panay/Filipino ancestry or family history, and confirmatory genetic testing for the TAF1 intron 32 SVA insertion/associated haplotype; repeat sizing and long-read/nanopore approaches are relevant for research and may aid molecular characterization	Review	(pozojevic2022factorsinfluencingreduced pages 1-2, pozojevic2022xlinkeddystoniaparkinsonismover pages 5-6, crombie2024therolesof pages 11-13)
Intervention landscape	Current care is largely symptomatic/supportive; mechanistically motivated experimental avenues include SVA excision, splicing correction, G4 destabilization, and modulation of epigenetic repressors/TAF1 expression	Review + primary	(nicoletto2024gquadruplexesinan pages 1-2, crombie2024therolesof pages 13-14, pozojevic2022xlinkeddystoniaparkinsonismover pages 2-4)
Trial: focused ultrasound	NCT05592028: MR-guided focused ultrasound pallidothalamic tractotomy, expanded access, AVAILABLE; adult genetically confirmed male XDP; outcomes include XDP-MDSP scale, XDP clinical/functional staging, BFMDRS, UPDRS with follow-up to 12 months	Clinical trial registry	(NCT05592028 chunk 1)
Trial: nutritional support	NCT03019458: MINGO supplement trial, randomized open-label, COMPLETED, n = 50; intervention = moringa/rice/mung-bean supplement for 12 weeks; primary endpoint = BMI; secondary endpoints = mortality, infectious-cause hospitalizations, MUAC	Clinical trial registry	(NCT03019458 chunk 1)
Trial: sensorimotor / DBS assessment	NCT05713721: observational sensorimotor integration study including DYT/PARK-TAF1 carriers; evaluates TMS short-latency afferent inhibition, video-based clinical outcomes, and effects of deep brain stimulation on/off in symptomatic participants	Clinical trial registry	(NCT05713721 chunk 2, NCT05713721 chunk 1)

Table: This table condenses the main structured facts about X-linked dystonia-parkinsonism across identifiers, genetics, modifiers, epidemiology, clinical features, mechanisms, biomarkers, and current trial activity. It is designed to support rapid knowledge-base population while preserving traceability to the gathered evidence.

Key limitations of this synthesis (evidence gaps)

Orphanet/MONDO/MeSH/ICD identifiers were not recoverable from the tool-accessible corpus and should be added from external ontology resources.
Detailed, standardized diagnostic criteria and differential diagnosis algorithms were not present in retrieved sources.
Many mechanistic and therapeutic directions (e.g., splicing-targeted ASOs, gene editing) are supported primarily by cell-model work referenced in reviews; additional clinical translation evidence was not retrievable here.

References

(pozojevic2022xlinkeddystoniaparkinsonismover pages 1-2): Jelena Pozojevic, Joseph Neos Cruz, and Ana Westenberger. X-linked dystonia-parkinsonism: over and above a repeat disorder. Medizinische Genetik, 33:319-324, Dec 2022. URL: https://doi.org/10.1515/medgen-2021-2105, doi:10.1515/medgen-2021-2105. This article has 8 citations.
(pozojevic2022factorsinfluencingreduced pages 1-2): J. Pozojevic, Björn-Hergen Laabs von Holt, and A. Westenberger. Factors influencing reduced penetrance and variable expressivity in x-linked dystonia-parkinsonism. Medizinische Genetik, 34:97-102, Jun 2022. URL: https://doi.org/10.1515/medgen-2022-2135, doi:10.1515/medgen-2022-2135. This article has 4 citations.
(nicoletto2024gquadruplexesinan pages 1-2): Giulia Nicoletto, Marianna Terreri, Ilaria Maurizio, Emanuela Ruggiero, Filippo M Cernilogar, Christine A Vaine, Maria Vittoria Cottini, Irina Shcherbakova, Ellen B Penney, Irene Gallina, David Monchaud, D Cristopher Bragg, Gunnar Schotta, and Sara N Richter. G-quadruplexes in an sva retrotransposon cause aberrant taf1 gene expression in x-linked dystonia parkinsonism. Nucleic Acids Research, 52:11571-11586, Sep 2024. URL: https://doi.org/10.1093/nar/gkae797, doi:10.1093/nar/gkae797. This article has 26 citations and is from a highest quality peer-reviewed journal.
(horvath2024miniheterochromatindomainsconstrain pages 1-2): Vivien Horváth, Raquel Garza, Marie E. Jönsson, Pia A. Johansson, Anita Adami, Georgia Christoforidou, Ofelia Karlsson, Laura Castilla Vallmanya, Symela Koutounidou, Patricia Gerdes, Ninoslav Pandiloski, Christopher H. Douse, and Johan Jakobsson. Mini-heterochromatin domains constrain the cis-regulatory impact of sva transposons in human brain development and disease. Nature Structural & Molecular Biology, 31:1543-1556, Jun 2024. URL: https://doi.org/10.1038/s41594-024-01320-8, doi:10.1038/s41594-024-01320-8. This article has 25 citations and is from a highest quality peer-reviewed journal.
(jamora2023transcranialmagneticresonanceguided pages 1-2): Roland Dominic G. Jamora, Kathleen Joy O. Khu, Marie Charmaine C. Sy, Juan Silvestre G. Pascual, Gerardo D. Legaspi, and Jose A. Aguilar. Transcranial magnetic resonance-guided focused ultrasound pallidothalamic tractotomy for patients with x-linked dystonia-parkinsonism: a study protocol. BMC Neurology, Aug 2023. URL: https://doi.org/10.1186/s12883-023-03344-x, doi:10.1186/s12883-023-03344-x. This article has 8 citations and is from a peer-reviewed journal.
(campion2022tissuespecificandrepeat pages 1-2): Lindsey N. Campion, Alan Mejia Maza, Rachita Yadav, Ellen B. Penney, Micaela G. Murcar, Kevin Correia, Tammy Gillis, Cara Fernandez-Cerado, M. Salvie Velasco-Andrada, G. Paul Legarda, Niecy G. Ganza-Bautista, J. Benedict B. Lagarde, Patrick J. Acuña, Trisha Multhaupt-Buell, Gabrielle Aldykiewicz, Melanie L. Supnet, Jan K. De Guzman, Criscely Go, Nutan Sharma, Edwin L. Munoz, Mark C. Ang, Cid Czarina E. Diesta, D. Cristopher Bragg, Laurie J. Ozelius, and Vanessa C. Wheeler. Tissue-specific and repeat length-dependent somatic instability of the x-linked dystonia parkinsonism-associated ccctct repeat. Acta Neuropathologica Communications, Apr 2022. URL: https://doi.org/10.1186/s40478-022-01349-0, doi:10.1186/s40478-022-01349-0. This article has 19 citations and is from a peer-reviewed journal.
(tshilenge2024proteomicanalysisof pages 1-2): Kizito-Tshitoko Tshilenge, Joanna Bons, Carlos Galicia Aguirre, Cristian Geronimo-Olvera, Samah Shah, Jacob Rose, Akos A. Gerencser, Sally K. Mak, Michelle E. Ehrlich, D. Cristopher Bragg, Birgit Schilling, and Lisa M. Ellerby. Proteomic analysis of x-linked dystonia parkinsonism disease striatal neurons reveals altered rna metabolism and splicing. Jan 2024. URL: https://doi.org/10.1016/j.nbd.2023.106367, doi:10.1016/j.nbd.2023.106367. This article has 13 citations and is from a domain leading peer-reviewed journal.
(crombie2024therolesof pages 13-14): Elisa M. Crombie, Karen Cleverley, H. T. Marc Timmers, and Elizabeth M. C. Fisher. The roles of taf1 in neuroscience and beyond. Royal Society Open Science, Sep 2024. URL: https://doi.org/10.1098/rsos.240790, doi:10.1098/rsos.240790. This article has 15 citations and is from a peer-reviewed journal.
(crombie2024therolesof pages 11-13): Elisa M. Crombie, Karen Cleverley, H. T. Marc Timmers, and Elizabeth M. C. Fisher. The roles of taf1 in neuroscience and beyond. Royal Society Open Science, Sep 2024. URL: https://doi.org/10.1098/rsos.240790, doi:10.1098/rsos.240790. This article has 15 citations and is from a peer-reviewed journal.
(pozojevic2022xlinkeddystoniaparkinsonismover pages 2-4): Jelena Pozojevic, Joseph Neos Cruz, and Ana Westenberger. X-linked dystonia-parkinsonism: over and above a repeat disorder. Medizinische Genetik, 33:319-324, Dec 2022. URL: https://doi.org/10.1515/medgen-2021-2105, doi:10.1515/medgen-2021-2105. This article has 8 citations.
(crombie2024therolesof pages 1-2): Elisa M. Crombie, Karen Cleverley, H. T. Marc Timmers, and Elizabeth M. C. Fisher. The roles of taf1 in neuroscience and beyond. Royal Society Open Science, Sep 2024. URL: https://doi.org/10.1098/rsos.240790, doi:10.1098/rsos.240790. This article has 15 citations and is from a peer-reviewed journal.
(rosenkrantz2024znf91isan pages 1-2): Jimi L. Rosenkrantz, J. Elias Brandorff, Sanaz Raghib, Ashni Kapadia, Christine A. Vaine, D. Cristopher Bragg, Grace Farmiloe, and Frank M. J. Jacobs. Znf91 is an endogenous repressor of the molecular phenotype associated with x-linked dystonia–parkinsonism (xdp). Proceedings of the National Academy of Sciences of the United States of America, Aug 2024. URL: https://doi.org/10.1073/pnas.2401217121, doi:10.1073/pnas.2401217121. This article has 8 citations and is from a highest quality peer-reviewed journal.
(tshilenge2024proteomicanalysisof pages 2-4): Kizito-Tshitoko Tshilenge, Joanna Bons, Carlos Galicia Aguirre, Cristian Geronimo-Olvera, Samah Shah, Jacob Rose, Akos A. Gerencser, Sally K. Mak, Michelle E. Ehrlich, D. Cristopher Bragg, Birgit Schilling, and Lisa M. Ellerby. Proteomic analysis of x-linked dystonia parkinsonism disease striatal neurons reveals altered rna metabolism and splicing. Jan 2024. URL: https://doi.org/10.1016/j.nbd.2023.106367, doi:10.1016/j.nbd.2023.106367. This article has 13 citations and is from a domain leading peer-reviewed journal.
(horvath2024miniheterochromatindomainsconstrain media 7af698dd): Vivien Horváth, Raquel Garza, Marie E. Jönsson, Pia A. Johansson, Anita Adami, Georgia Christoforidou, Ofelia Karlsson, Laura Castilla Vallmanya, Symela Koutounidou, Patricia Gerdes, Ninoslav Pandiloski, Christopher H. Douse, and Johan Jakobsson. Mini-heterochromatin domains constrain the cis-regulatory impact of sva transposons in human brain development and disease. Nature Structural & Molecular Biology, 31:1543-1556, Jun 2024. URL: https://doi.org/10.1038/s41594-024-01320-8, doi:10.1038/s41594-024-01320-8. This article has 25 citations and is from a highest quality peer-reviewed journal.
(crombie2024therolesof pages 14-16): Elisa M. Crombie, Karen Cleverley, H. T. Marc Timmers, and Elizabeth M. C. Fisher. The roles of taf1 in neuroscience and beyond. Royal Society Open Science, Sep 2024. URL: https://doi.org/10.1098/rsos.240790, doi:10.1098/rsos.240790. This article has 15 citations and is from a peer-reviewed journal.
(NCT05592028 chunk 1): Roland Dominic G. Jamora. High Intensity Focused Ultrasound for X-linked Dystonia-parkinsonism. University of the Philippines Manila - Philippine General Hospital. ClinicalTrials.gov Identifier: NCT05592028
(jamora2023transcranialmagneticresonanceguided pages 2-4): Roland Dominic G. Jamora, Kathleen Joy O. Khu, Marie Charmaine C. Sy, Juan Silvestre G. Pascual, Gerardo D. Legaspi, and Jose A. Aguilar. Transcranial magnetic resonance-guided focused ultrasound pallidothalamic tractotomy for patients with x-linked dystonia-parkinsonism: a study protocol. BMC Neurology, Aug 2023. URL: https://doi.org/10.1186/s12883-023-03344-x, doi:10.1186/s12883-023-03344-x. This article has 8 citations and is from a peer-reviewed journal.
(NCT03019458 chunk 1): MINGO Supplemental Trial in X-linked Dystonia-Parkinsonism Patients. Sunshine Care Foundation. 2017. ClinicalTrials.gov Identifier: NCT03019458
(NCT05713721 chunk 2): Anne Weißbach. Sensorimotor Integration in Monogenic Parkinson-dystonia Syndromes. University Hospital Schleswig-Holstein. 2023. ClinicalTrials.gov Identifier: NCT05713721
(pozojevic2022xlinkeddystoniaparkinsonismover pages 4-5): Jelena Pozojevic, Joseph Neos Cruz, and Ana Westenberger. X-linked dystonia-parkinsonism: over and above a repeat disorder. Medizinische Genetik, 33:319-324, Dec 2022. URL: https://doi.org/10.1515/medgen-2021-2105, doi:10.1515/medgen-2021-2105. This article has 8 citations.
(horvath2024miniheterochromatindomainsconstrain pages 10-11): Vivien Horváth, Raquel Garza, Marie E. Jönsson, Pia A. Johansson, Anita Adami, Georgia Christoforidou, Ofelia Karlsson, Laura Castilla Vallmanya, Symela Koutounidou, Patricia Gerdes, Ninoslav Pandiloski, Christopher H. Douse, and Johan Jakobsson. Mini-heterochromatin domains constrain the cis-regulatory impact of sva transposons in human brain development and disease. Nature Structural & Molecular Biology, 31:1543-1556, Jun 2024. URL: https://doi.org/10.1038/s41594-024-01320-8, doi:10.1038/s41594-024-01320-8. This article has 25 citations and is from a highest quality peer-reviewed journal.
(rosenkrantz2024znf91isan pages 8-9): Jimi L. Rosenkrantz, J. Elias Brandorff, Sanaz Raghib, Ashni Kapadia, Christine A. Vaine, D. Cristopher Bragg, Grace Farmiloe, and Frank M. J. Jacobs. Znf91 is an endogenous repressor of the molecular phenotype associated with x-linked dystonia–parkinsonism (xdp). Proceedings of the National Academy of Sciences of the United States of America, Aug 2024. URL: https://doi.org/10.1073/pnas.2401217121, doi:10.1073/pnas.2401217121. This article has 8 citations and is from a highest quality peer-reviewed journal.
(rosenkrantz2024znf91isan pages 7-8): Jimi L. Rosenkrantz, J. Elias Brandorff, Sanaz Raghib, Ashni Kapadia, Christine A. Vaine, D. Cristopher Bragg, Grace Farmiloe, and Frank M. J. Jacobs. Znf91 is an endogenous repressor of the molecular phenotype associated with x-linked dystonia–parkinsonism (xdp). Proceedings of the National Academy of Sciences of the United States of America, Aug 2024. URL: https://doi.org/10.1073/pnas.2401217121, doi:10.1073/pnas.2401217121. This article has 8 citations and is from a highest quality peer-reviewed journal.
(pozojevic2022xlinkeddystoniaparkinsonismover pages 5-6): Jelena Pozojevic, Joseph Neos Cruz, and Ana Westenberger. X-linked dystonia-parkinsonism: over and above a repeat disorder. Medizinische Genetik, 33:319-324, Dec 2022. URL: https://doi.org/10.1515/medgen-2021-2105, doi:10.1515/medgen-2021-2105. This article has 8 citations.
(NCT05713721 chunk 1): Anne Weißbach. Sensorimotor Integration in Monogenic Parkinson-dystonia Syndromes. University Hospital Schleswig-Holstein. 2023. ClinicalTrials.gov Identifier: NCT05713721

Artifacts

Edison artifact artifact-00

Ask OpenScientist

OpenScientist Report

Inheritance

Mechanistic Hypotheses

Pathophysiology

Pathograph

Phenotypes

Genetic Associations

Medical Actions

Clinical Trials

Source YAML

References & Deep Research

References

Deep Research

X-linked Dystonia–Parkinsonism (XDP; “Lubag”) — Comprehensive Disease Characteristics Report

Target disease

Executive summary (current understanding)

1. Disease information

1.1 What is the disease?

1.2 Key identifiers

1.3 Synonyms / alternative names

1.4 Evidence type note

2. Etiology

2.1 Primary causal factors (genetic)

2.2 Risk factors

2.3 Protective factors

2.4 Gene–environment interactions

3. Phenotypes

3.1 Core phenotype spectrum (with suggested HPO terms)

3.2 Age of onset / severity / progression

3.3 Quality of life impact

4. Genetic / molecular information

4.1 Causal gene(s)

4.2 Pathogenic variant type/class

4.3 Modifier genes

4.4 Epigenetic information

5. Environmental information

6. Mechanism / pathophysiology

6.1 Causal chain (from variant to phenotype)

6.2 Molecular pathways and processes (suggested GO terms)

6.3 Cell types (suggested CL terms)

6.4 Anatomical structures (suggested UBERON terms)

6.5 Visual evidence (locus + intron retention)

7. Anatomical structures affected

8. Temporal development

9. Inheritance and population

10. Diagnostics

10.1 Clinical diagnosis

10.2 Genetic testing (confirmatory)

10.3 Molecular/omics assays used in recent research (informing diagnostic biomarker development)

10.4 Differential diagnosis

11. Outcome / prognosis

12. Treatment

12.1 Symptomatic pharmacotherapy and chemodenervation (real-world practice)

12.2 Deep brain stimulation (DBS)

12.3 Ablative and incisionless interventions: MR-guided focused ultrasound (MRgFUS)

12.4 Experimental / precision-medicine directions (preclinical)

13. Prevention

14. Other species / natural disease

15. Model organisms / model systems

15.1 Human cellular models (high relevance)

15.2 Non-human models

Recent developments (prioritizing 2023–2024)

Current applications / real-world implementations

Clinical trials and registries (URLs + key metadata)

Statistics and data highlights (human studies)

Structured summary table

Key limitations of this synthesis (evidence gaps)

Artifacts